NCT00619242View on ClinicalTrials.gov

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

NATerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Esophageal Cancer
Interventions
DRUG

sorafenib

2 tablets with water by mouth twice a day for two weeks.

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Chicago

OTHER

NCT00619242 - The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer | Biotech Hunter | Biotech Hunter